brolucizumab Beovu
Selected indexed studies
- ** (, 2023) [PMID:37883618]
- ** (, 2023) [PMID:38502772]
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. (Ophthalmology, 2020) [PMID:30986442]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Brolucizumab. (2006) pubmed
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. (2020) pubmed
- Brolucizumab: First Approval. (2019) pubmed
- KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema. (2022) pubmed
- PMID:37883618 (2023) pubmed
- PMID:38502772 (2023) pubmed
- PMID:33347111 (2020) pubmed
- Brolucizumab (Beovu) for age-related macular degeneration. (2020) pubmed
- PMID:33301280 (2020) pubmed
- PMID:33301279 (2020) pubmed